Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 9—September 2019
Research

Genetic Characterization and Enhanced Surveillance of Ceftriaxone-Resistant Neisseria gonorrhoeae Strain, Alberta, Canada, 2018

Byron M. BerengerComments to Author , Walter Demczuk, Jennifer Gratrix, Kanti Pabbaraju, Petra Smyczek, and Irene Martin
Author affiliations: University of Calgary, Calgary, Alberta, Canada (B. Berenger); Alberta Public Laboratories, Calgary (B. Berenger, K. Pabbaraju); Public Health Agency of Canada, Winnipeg, Manitoba, Canada (W. Demczuk, I. Martin); Alberta Health Services, Edmonton, Alberta (J. Gratrix, P. Smyczek)

Main Article

Table 2

Test results and antimicrobial resistance pattern predictions of sequence types identified from enhanced surveillance of Neisseria gonorrhoeae samples, Alberta, Canada*

Sequence type by NG-MAST No. specimens
(% of all specimens), n = 232† No. cases, n = 194† Antimicrobial resistance pattern prediction‡ No. specimens with specified AMR/no. cultures identified with ST§
Nontypeable 59 (25.4) 35 NA
ST8890 34 (14.7) 33 TetR 43/45
ST5441 17 (7.3) 17 Susceptible 66/79
ST16065 12 (5.2) 9 CipR/TetR 63/63
ST14788 7 (3.0) 6 Susceptible 21/26
ST5985 7 (3.0) 7 TRNG 649/730
ST11086 6 (2.6) 5 CipR/EryR/PenR/TetR 30/30
ST12302 6 (2.6) 6 CipR/EryR/TetR/often AziR 1,198/1,211 (CipR/EryR/TetR);
687/1,211 (are also AziR)
ST4637 6 (2.6) 5 Susceptible 17/20
ST8288 6 (2.6) 6 Penicillinase-producing/CipR 12/14
ST1387§ 4 (1.7) 4 No culture available 0
ST16288 4 (1.7) 4 CipR/EryR 26/26
ST16972 4 (1.7) 4 Susceptible 4/5
ST17029 4 (1.7) 4 No culture available 0
ST18135 4 (1.7) 2 No culture available 0
ST4186 4 (1.7) 4 Susceptible 4/4
ST11461 3 (1.3) 3 TRNG 161/166
ST13489 3 (1.3) 3 Susceptible 1/1
ST16211 3 (1.3) 2 EryR/TetR 2/2
ST14698 2 (0.86) 2 AziR/CipR/EryR/TetR 142/208
ST16825§ 2 (0.86) 1 No culture available 0
ST18126§ 2 (0.86) 2 No culture available 0
ST18154 2 (0.86) 2 No culture available 0

*N. gonorrhoeae infection was diagnosed by the Aptima Combo 2 nucleic acid amplification test kit (Hologic Inc., https://www.hologic.com). AziR, azithromycin resistant; CipR, ciprofloxacin resistant; EryR, erythromycin resistant; NG-MAST, N. gonorrhoeae multiantigen sequence typing; ST, sequence type; TetR, tetracycline-resistant; TRNG, TetR N. gonorrhoeae (high-level plasmid mediated).
†Sequence types detected in only 1 specimen and resistance patterns (if known) are as follows and represent individual cases unless noted as an additional site: ST10451 (PenR/CipR/EryR/TetR); ST11691 (CipR/EryR/TetR and half are AziR); ST11933 (susceptible or TetR); ST-16161 (TetR); ST16595 (TRNG); ST18146; ST18156; ST3935 (EryR/TetR, sometimes PenR); ST9120. Sequence types detected in only 1 specimen that had not previously been detected in Alberta are ST14797; ST17196; ST18057; ST18134; ST18136; ST18137; ST18138; ST18155 (additional site); ST18157; ST18158; ST18159; ST18160; ST18161; ST18162; ST18340 (additional site); ST18341; ST18342; ST18343; ST18344; ST18345 (additional site); ST5308 (XDR: AzR/CeDS/CipR/PenR/TetR/EryR); ST6339.
‡Based on data from the Canadian national gonococcal collection, which included 7,498 gonococcal cultures with sequence typing and phenotypic susceptibility results collected 2016–2018.
§Sequence type had not been previously detected in Alberta.

Main Article

Page created: August 21, 2019
Page updated: August 21, 2019
Page reviewed: August 21, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external